Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma
Study Information
Alliance Study ID: CALGB 10301
NCT Study ID (ClinicalTrials.gov): NCT00088855
Alliance Committee: Leukemia
Disease or Cancer Type: Multiple Myeloma & Plasma Cell Disorders
Alliance Study Chair: Robert Z Orlowski
Status: COMPLETED
Study Description
This phase II trial studies the side effects and how well bortezomib and pegylated liposomal doxorubicin hydrochloride work in treating patients multiple myeloma that are experiencing symptoms and have not received prior treatment. Bortezomib and pegylated liposomal doxorubicin hydrochloride may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information